Free Trial
→ Trump’s treachery (From Porter & Company) (Ad)
NYSE:RFL

Rafael 12/14/2023 Earnings Report

Rafael logo
$1.43 +0.03 (+2.14%)
Closing price 05/30/2025 03:58 PM Eastern
Extended Trading
$1.42 0.00 (-0.35%)
As of 05/30/2025 06:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

Rafael EPS Results

Actual EPS
-$0.08
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Rafael Revenue Results

Actual Revenue
$0.07 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rafael Announcement Details

Quarter
Date
12/14/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Rafael's Q3 2025 earnings is scheduled for Friday, June 13, 2025, with a conference call scheduled on Tuesday, June 10, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Rafael Earnings Headlines

Facing Braves, Boston’s Rafael Devers looks to end May with a bang
June 1 at 8:11 AM | msn.com
Red Sox-Rafael Devers Drama Gets Likely Final Twist Of 2025
May 31 at 9:29 PM | msn.com
“You all just got a lot richer”
Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.
June 1, 2025 | Brownstone Research (Ad)
Red Sox’s Craig Breslow reveals insight on Rafael Devers first base conversations
May 31 at 9:29 PM | msn.com
Red Sox reportedly not expecting Rafael Devers to play defense in 2025
May 31 at 3:43 AM | msn.com
Red Sox make Rafael Devers fielding decision after long controversy
May 30 at 10:42 PM | msn.com
See More Rafael Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rafael? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rafael and other key companies, straight to your email.

About Rafael

Rafael (NYSE:RFL) primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

View Rafael Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles